XILI TECHNOLOGY(SH:688616)2022-10-26 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥183,870,765.47, representing a year-on-year increase of 117.99%[5] - The net profit attributable to shareholders for Q3 2022 was ¥19,154,359.20, an increase of 98.84% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥18,534,712.09, reflecting a growth of 107.19% year-on-year[5] - Total revenue for the first three quarters of 2022 reached ¥388,579,961.16, a significant increase of 44.7% compared to ¥268,698,658.97 in the same period of 2021[22] - Net profit for the third quarter was ¥46,424,434.35, compared to ¥44,439,957.84 in the same quarter of 2021, indicating an increase of 4.5%[23] - The company's net profit for the first three quarters of 2022 reached CNY 22,727,976.94, a significant improvement from a net loss of CNY 5,956,736.56 in the same period of 2021[25] - The company reported a total comprehensive income of CNY 46,424,434.35 for Q3 2022, with CNY 44,861,816.71 attributable to the parent company[24] Research and Development - Research and development expenses totaled ¥8,319,581.48 for Q3 2022, up 74.42% from the previous year[6] - Research and development expenses for the third quarter amounted to ¥20,816,526.68, which is a 48.9% increase from ¥13,991,001.28 in the previous year[23] - The company plans to continue increasing its investment in overseas product research and development to support future growth[10] Assets and Liabilities - The total assets at the end of the reporting period were ¥957,419,943.25, an increase of 2.28% compared to the end of the previous year[6] - Total assets as of the end of the third quarter were ¥957,419,943.25, slightly up from ¥936,122,392.32 at the end of the previous year[19] - Total liabilities increased to ¥213,443,935.87 from ¥204,070,819.29, marking a rise of 6.7%[19] - The company's total equity increased to ¥743,976,007.38 from ¥732,051,573.03, showing a growth of 1.3%[19] Cash Flow - The company reported a cash flow from operating activities of ¥22,727,976.94 for the year-to-date period[6] - Cash inflow from operating activities was CNY 393,620,796.69, compared to CNY 285,347,666.88 in the previous year, indicating a year-over-year increase of approximately 38%[25] - Cash and cash equivalents decreased to ¥178,425,204.53 from ¥348,366,410.62, a decline of 48.9%[17] - Total cash and cash equivalents at the end of the period were CNY 165,505,430.33, down from CNY 195,003,900.69 at the end of the previous year[26] - The company reported a cash outflow from financing activities of CNY 34,632,764.19, compared to an inflow of CNY 179,197,798.54 in the same period last year[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,667[12] - The largest shareholder, Song Yiran, holds a 4.34% stake with 6,510,000 shares[12] - The second largest shareholder, Chen Long, holds 2.30% with 2,700,000 shares[12] - The company reported a total of 49,830,000 shares held by domestic individuals, representing 33.2% of the total shares[12] - The company has 21,600,000 shares held by another domestic individual, accounting for 14.4%[12] - The report indicates that there are no significant related party transactions among the top ten shareholders[13] - The company has not disclosed any financing or margin trading activities involving its shares[13] Operational Insights - The increase in revenue was primarily driven by significant growth in overseas market sales and HPLC module revenue compared to the previous year[10] - The report does not highlight any significant operational issues during the reporting period[14] - The company emphasizes the importance of monitoring its operational performance in future reports[14] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[27]